AbbVie, Inc. (ABBV)

Over the past six months, AbbVie's stock price has seen an increase. Key events impacting ABBV's stock price include biosimilar competition for Humira, which led to a decline in global sales but was offset by strong performance from Skyrizi, resulting in raised 2024 EPS guidance. AbbVie anticipates a significant financial impact in Q3 2025 due to expenses related to acquired IPR&D and milestone obligations, leading to a revised full-year 2025 adjusted diluted earnings per share forecast. AbbVie announced the start of construction for a new API manufacturing plant in North Chicago, Illinois, as part of a commitment to invest over $10 billion in U.S. capital over the next decade.

AbbVie's business generally does not experience significant seasonality. However, product revenues can be influenced by several factors, including end customer and retail buying patterns, as well as fluctuations in wholesaler inventory levels. In the United States, AbbVie distributes its pharmaceutical products primarily through independent wholesale distributors.

AbbVie Inc. is a research-based biopharmaceutical company that spun off from Abbott Laboratories in 2013, operating within the healthcare sector, specifically the pharmaceutical industry. AbbVie's core business segments primarily focus on immunology, oncology, neuroscience, aesthetics, and eye care. Major products include Humira, Skyrizi, and Rinvoq for autoimmune diseases; Imbruvica, Venclexta, and Elahere for various cancers; Botox Therapeutic, Ubrelvy, Qulipta, and Vraylar for neurological conditions; and Botox Cosmetic and Juvederm for aesthetics.

AbbVie's corporate headquarters are located in North Chicago, Illinois, United States, and it operates in over 70 countries, marketing its products in more than 170 countries worldwide. Manufacturing facilities are located in the U.S., Puerto Rico, Italy, Ireland, Germany, and Singapore, while principal R&D facilities outside the U.S. are in Ludwigshafen, Germany, and Tokyo, Japan. The United States is AbbVie's largest market, representing 76.38% of its total revenue in fiscal year 2024, with non-U.S. markets accounting for 23.62%.

AbbVie strives to have a remarkable impact on people's lives through innovative medicines and solutions, emphasizing its commitment to science, patients, and sustainability. However, AbbVie has faced challenges to its brand reputation, primarily stemming from product-related lawsuits alleging that its products caused serious injuries and deaths due to a failure to warn about risks. In March 2018, AbbVie's multiple sclerosis drug Zinbryta was recalled after leading to the deaths of three patients. AbbVie has been actively engaged in legal battles to protect its Humira patent estate against biosimilar competition, filing numerous patents to block rivals.

AbbVie Inc. has a diverse ownership structure, with institutional investors holding a significant portion of the company's stock. Approximately 57.19% of the company's stock is owned by institutional investors, with Vanguard Group Inc, BlackRock, Inc., State Street Corp, JPMorgan Chase & Co, and Morgan Stanley being some of the largest shareholders. Overall, institutional investors own about 66% of AbbVie's shares, while retail investors and insiders collectively own about 34% of the company. Vanguard Group Inc is noted as the largest individual AbbVie shareholder, owning 10.04% of the company's shares.